Milestone Pharmaceuticals Inc. (MIST) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Milestone Pharmaceuticals Inc. (MIST) Earnings Overview
As of June 28, 2026, Milestone Pharmaceuticals Inc. (MIST) reported trailing twelve-month net income of -$68M, reflecting -11.9% year-over-year growth. The company earned $-0.52 per diluted share over the past four quarters, with a net profit margin of -4078.8%.
Looking at the long-term picture, MIST's historical earnings data spans multiple years. The company achieved its highest annual net income of -$8M in fiscal 2017.
Milestone Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), PRAX (-$327M net income), XENE (-$383M net income, -4612.1% margin), MIST has room to improve margins relative to the peer group. Compare MIST vs ACAD →
MIST Earnings vs Peers
Earnings metrics vs comparable public companies
MIST Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$63M | -51.9% | -$62M | $-0.75 | -4078.8% | -4041.7% |
| 2024 | -$42M | +30.4% | -$42M | $-0.67 | - | - |
| 2023 | -$60M | -2.2% | -$61M | $-1.39 | -5968.5% | -6109.8% |
| 2022 | -$58M | -36.3% | -$60M | $-1.35 | -1167.8% | -1192.8% |
| 2021 | -$43M | +14.2% | -$43M | $-1.02 | -285.7% | -287.2% |
| 2020 | -$50M | +9.5% | -$51M | $-1.70 | - | - |
| 2019 | -$55M | -138.2% | -$58M | $-3.50 | - | - |
| 2018 | -$23M | -186.7% | -$24M | $-0.98 | - | - |
| 2017 | -$8M | - | -$8M | $-0.34 | - | - |
Download Data
Export MIST earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MIST — Frequently Asked Questions
Quick answers to the most common questions about buying MIST stock.
What is MIST earnings per share (EPS)?
MIST trailing twelve-month (TTM) diluted EPS is $-0.52, reflecting -11.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Milestone Pharmaceuticals Inc.'s net income?
Milestone Pharmaceuticals Inc. (MIST) trailing twelve-month net income is $-68M as of 2025. Earnings declined -11.9% year-over-year.
Is MIST profitable?
MIST is not currently profitable on a TTM basis, reporting a net loss of $-68M. Net margin is -4078.8%. Investors should monitor for a return to profitability.
What is MIST's earnings growth rate?
MIST compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are MIST's profit margins?
Milestone Pharmaceuticals Inc. net profit margin is -4078.8%, operating margin is -4041.7%, and gross margin is +92.6%. Below-average margins reflect competitive or cost pressures. Return on Equity is -229.7%.
Is MIST growing earnings?
MIST earnings are declining — EPS fell -11.9% year-over-year. TTM net income dropped to $-68M. This contrasts with the 5-year CAGR of N/A.
What was MIST's best earnings year?
Milestone Pharmaceuticals Inc.'s highest annual net income on record is $-8M, achieved in fiscal year 2017. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were MIST's earnings last quarter?
MIST's most recent reported quarter was Q1 2026. Net income was $-26M with diluted EPS of $-0.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.